Literature DB >> 21471195

High avidity binding to DNA protects ubiquitylated substrates from proteasomal degradation.

Giuseppe Coppotelli1, Nouman Mughal, Diego Marescotti, Maria G Masucci.   

Abstract

Protein domains that act as degradation and stabilization signals regulate the rate of turnover of proteasomal substrates. Here we report that the bipartite Gly-Arg repeat of the Epstein-Barr virus (EBV) nuclear antigen (EBNA)-1 acts as a stabilization signal that inhibits proteasomal degradation in the nucleus by promoting binding to cellular DNA. Protection can be transferred by grafting the domain to unrelated proteasomal substrates and does not involve changes of ubiquitylation. Protection is also afforded by other protein domains that, similar to the Gly-Arg repeat, mediate high avidity binding to DNA, as exemplified by resistance to detergent extraction. Our findings identify high avidity binding to DNA as a portable inhibitory signal that counteracts proteasomal degradation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471195      PMCID: PMC3103336          DOI: 10.1074/jbc.M111.224782

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Nuclear import of Epstein-Barr virus nuclear antigen 1 mediated by NPI-1 (Importin alpha5) is up- and down-regulated by phosphorylation of the nuclear localization signal for which Lys379 and Arg380 are essential.

Authors:  Ryo Kitamura; Toshihiro Sekimoto; Sayuri Ito; Shizuko Harada; Hideo Yamagata; Hisao Masai; Yoshihiro Yoneda; Kazuo Yanagi
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

Authors:  J Levitskaya; M Coram; V Levitsky; S Imreh; P M Steigerwald-Mullen; G Klein; M G Kurilla; M G Masucci
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

3.  Degradation of myogenic transcription factor MyoD by the ubiquitin pathway in vivo and in vitro: regulation by specific DNA binding.

Authors:  O Abu Hatoum; S Gross-Mesilaty; K Breitschopf; A Hoffman; H Gonen; A Ciechanover; E Bengal
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

4.  A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis.

Authors:  A Sharipo; M Imreh; A Leonchiks; S Imreh; M G Masucci
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

5.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

Authors:  J Levitskaya; A Sharipo; A Leonchiks; A Ciechanover; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

6.  The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif.

Authors:  J R Huth; C A Bewley; M S Nissen; J N Evans; R Reeves; A M Gronenborn; G M Clore
Journal:  Nat Struct Biol       Date:  1997-08

7.  Competition between HMG-I(Y), HMG-1 and histone H1 on four-way junction DNA.

Authors:  D A Hill; R Reeves
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

8.  RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase.

Authors:  Yongwon Jung; Stephen J Lippard
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

9.  Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs.

Authors:  E Robertson; E Kieff
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinase gene.

Authors:  M Ossevoort; A Zaldumbide; S J Cramer; E I H van der Voort; R E M Toes; R C Hoeben
Journal:  Cancer Gene Ther       Date:  2006-06       Impact factor: 5.987

View more
  7 in total

1.  Interaction between basic residues of Epstein-Barr virus EBNA1 protein and cellular chromatin mediates viral plasmid maintenance.

Authors:  Teru Kanda; Naoki Horikoshi; Takayuki Murata; Daisuke Kawashima; Atsuko Sugimoto; Yohei Narita; Hitoshi Kurumizaka; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

2.  Phosphorylation regulates binding of the human papillomavirus type 8 E2 protein to host chromosomes.

Authors:  Vandana Sekhar; Alison A McBride
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

3.  Evolutionary Variation in MADS Box Dimerization Affects Floral Development and Protein Abundance in Maize.

Authors:  María Jazmín Abraham-Juárez; Amanda Schrager-Lavelle; Jarrett Man; Clinton Whipple; Pubudu Handakumbura; Courtney Babbitt; Madelaine Bartlett
Journal:  Plant Cell       Date:  2020-09-01       Impact factor: 11.277

4.  Interaction of gamma-herpesvirus genome maintenance proteins with cellular chromatin.

Authors:  Nouman Mughal; Giuseppe Coppotelli; Simone Callegari; Stefano Gastaldello; Maria G Masucci
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

5.  The Epstein-Barr virus nuclear antigen-1 reprograms transcription by mimicry of high mobility group A proteins.

Authors:  Giuseppe Coppotelli; Nouman Mughal; Simone Callegari; Ramakrishna Sompallae; Laia Caja; Martijn S Luijsterburg; Nico P Dantuma; Aristidis Moustakas; Maria G Masucci
Journal:  Nucleic Acids Res       Date:  2013-01-28       Impact factor: 16.971

6.  Macavirus latency-associated protein evades immune detection through regulation of protein synthesis in cis depending upon its glycin/glutamate-rich domain.

Authors:  Océane Sorel; Ting Chen; Françoise Myster; Justine Javaux; Alain Vanderplasschen; Benjamin G Dewals
Journal:  PLoS Pathog       Date:  2017-10-23       Impact factor: 6.823

Review 7.  The Critical Role of Genome Maintenance Proteins in Immune Evasion During Gammaherpesvirus Latency.

Authors:  Océane Sorel; Benjamin G Dewals
Journal:  Front Microbiol       Date:  2019-01-09       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.